Exciting Advances in Immuno-Oncology Therapeutics at ESMO Congress 2024
iTeos Therapeutics Announces Interim Data from GALAXIES Lung-201 Study
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 20, 2024 (GLOBE NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that interim data from GALAXIES Lung-201, the Phase 2 platform study sponsored by iTeos’ development partner GSK, assessing the belrestotug + dostarlimab doublet in previously untreated, unresectable, locally advanced or metastatic PD-L1 high non-small cell lung cancer, will be presented as a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024, being held September 13-17, 2024 in Barcelona, Spain.
The presentation at ESMO Congress 2024 will provide insights into the ongoing advances in immuno-oncology therapy for patients with non-small cell lung cancer. The belrestotug + dostarlimab doublet being evaluated in the GALAXIES Lung-201 study has shown promising results in the treatment of previously untreated patients with PD-L1 high tumors. This innovative approach aims to improve outcomes for patients with advanced lung cancer by leveraging the power of the immune system to target cancer cells.
Impact on Individuals
For patients with non-small cell lung cancer, the interim data from the GALAXIES Lung-201 study presents a potential new treatment option that could improve outcomes and quality of life. The belrestotug + dostarlimab doublet offers hope for those diagnosed with unresectable or metastatic tumors, providing a promising avenue for more effective and targeted therapies.
Impact on the World
The advancements in immuno-oncology therapeutics showcased at ESMO Congress 2024 have the potential to revolutionize the treatment landscape for non-small cell lung cancer and other types of malignancies. By harnessing the body’s immune response to fight cancer, researchers are paving the way for more personalized and effective therapies that could benefit patients worldwide. The collaboration between iTeos and GSK highlights the importance of partnership and innovation in driving progress in the field of oncology.
Conclusion
As we look towards the future of cancer treatment, the interim data from the GALAXIES Lung-201 study represents a significant step forward in the development of immuno-oncology therapeutics. The findings presented at ESMO Congress 2024 offer hope for patients battling non-small cell lung cancer and underscore the potential for groundbreaking advancements in the fight against cancer. The collaboration between iTeos and GSK exemplifies the dedication and innovation needed to drive progress in oncology research and ultimately improve patient outcomes.
